Suzano (SUZB3) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jan, 2026Executive summary
Achieved record sales volumes in 2024, driven by the Ribas do Rio Pardo mill ramp-up, strong operational execution, and successful integration of new assets, especially in the U.S. and Brazil.
Integration of Suzano Packaging US (Pactiv Evergreen assets) added 870 employees and contributed to higher sales and global expansion.
Maintained tight pulp inventories and improved competitiveness through cost reductions and efficiency gains.
Adjusted EBITDA reached R$23.8 billion for 2024, with a 56% margin in the pulp business.
Net income turned to a loss of R$6.7 billion, mainly due to negative financial results from BRL depreciation and derivative losses.
Financial highlights
Full-year 2024 EBITDA reached R$23.8 billion, up from R$18.3 billion in 2023; operating cash generation at R$16.2 billion.
Net debt ended 2024 at US$12.8 billion, with net debt-to-EBITDA at 2.9x (USD basis), improved from 3.1x in 4Q23.
Pulp sales volume reached 10.9 million tons, up from 10.2 million in 2023; paper and packaging at 1.2 million tons.
Financial results impacted by a -$15.6 billion accounting loss due to FX variation and hedge mark-to-market.
Shareholder remuneration in 2024 totaled R$4.3 billion, including R$2.8 billion in buybacks and R$1.5 billion in interest on equity.
Outlook and guidance
Expects higher pulp sales volume in 2025 as Ribas mill reaches full capacity; U.S. paperboard demand projected to remain robust.
Cash cost ex-downtime for 2025 expected to be flattish versus Q4 2024, with a one-off increase in Q1 due to maintenance downtimes.
Management approved a 2025 capex budget of R$12.4 billion, with R$7.8 billion for industrial and forestry maintenance.
No transformational M&A deals planned; focus remains on value-creating, scalable downstream opportunities.
Ongoing focus on deleveraging.
Latest events from Suzano
- Record sales, cost discipline, and strong liquidity support a positive outlook.SUZB3
Q4 202511 Feb 2026 - EBITDA up 60% year-over-year, but net loss of R$3.77B on FX and derivative impacts.SUZB3
Q2 20241 Feb 2026 - EBITDA and sales volumes surged, with Ribas ramp-up and acquisitions boosting performance.SUZB3
Q3 202418 Jan 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - Net income rose to R$6.3B in 1Q25, with stable leverage and strong free cash flow.SUZB3
Q1 202518 Nov 2025 - JV creates a global tissue leader with $3.3bn revenue, $175M synergies, and strong diversification.SUZB3
Investor Update12 Nov 2025 - Cash cost below BRL 800/ton, EBITDA down 20%, leverage up, 2025 capex guidance reaffirmed.SUZB3
Q3 20257 Nov 2025